Asset Details
Do you wish to reserve the book?
Robust Kidney Abnormality Segmentation: A Validation Study of an AI-Based Framework
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Robust Kidney Abnormality Segmentation: A Validation Study of an AI-Based Framework
Do you wish to request the book?
Robust Kidney Abnormality Segmentation: A Validation Study of an AI-Based Framework
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
Robust Kidney Abnormality Segmentation: A Validation Study of an AI-Based Framework
2025
Overview
Kidney abnormality segmentation has important potential to enhance the clinical workflow, especially in settings requiring quantitative assessments. Kidney volume could serve as an important biomarker for renal diseases, with changes in volume correlating directly with kidney function. Currently, clinical practice often relies on subjective visual assessment for evaluating kidney size and abnormalities, including tumors and cysts, which are typically staged based on diameter, volume, and anatomical location. To support a more objective and reproducible approach, this research aims to develop a robust, thoroughly validated kidney abnormality segmentation algorithm, made publicly available for clinical and research use. We employ publicly available training datasets and leverage the state-of-the-art medical image segmentation framework nnU-Net. Validation is conducted using both proprietary and public test datasets, with segmentation performance quantified by Dice coefficient and the 95th percentile Hausdorff distance. Furthermore, we analyze robustness across subgroups based on patient sex, age, CT contrast phases, and tumor histologic subtypes. Our findings demonstrate that our segmentation algorithm, trained exclusively on publicly available data, generalizes effectively to external test sets and outperforms existing state-of-the-art models across all tested datasets. Subgroup analyses reveal consistent high performance, indicating strong robustness and reliability. The developed algorithm and associated code are publicly accessible at https://github.com/DIAGNijmegen/oncology-kidney-abnormality-segmentation.
